Effect of co-administration of alendronate and allan sodium phosphate for the management of osteoporosis

  • Jialian Chen
  • Xiong Peng
  • Fei Hu
Keywords: Osteoporosis, Allan sodium phosphate, Alendronate, Apoptosis-related factors, Calcium

Abstract

Purpose: To study the therapeutic effect of combination of alendronate and allan sodium phosphate on osteoporosis.
Methods: Patients diagnosed with osteoporosis (100) were randomly assigned to control and study groups (50 subjects/group). The control group received conventional calcium treatment (calcium carbonate D3) after surgery. They consisted of 21 males and 29 females aged 62 to 78 years. The observation group consisted of 22 males and 28 females aged 63 to 77 years (mean age = 68.90 ± 6.43 years), and were treated with sodium alendronate and allan sodium phosphate. Bone mineral density (BMD), bone pain score, clinical effectiveness and levels of calcium, phosphorus, osteocalcin, collagen N-terminal peptide (NTX) and urinary calcium/creatinine were determined using ELISA kits.
Results: After 1 year of treatment, lumbar vertebral and femoral neck BMD significantly increased in both groups. The study group had significantly higher BMD than the controls (p < 0.05). Blood calcium levels increased significantly after 1 year in both groups. The treatment led to a higher level of osteocalcin in the study group than in the control group (p < 0.05). However, the treatment brought about significantly lower NTX level in the study group than in controls.
Conclusion: The results indicate that combined administration of sodium alendronate and allan sodium phosphate is effective for the treatment of osteoporosis.

Keywords: Osteoporosis, Allan sodium phosphate, Alendronate, Apoptosis-related factors, Calcium

Section
Articles

Journal Identifiers


eISSN: 1596-9827
print ISSN: 1596-5996